Interprotein Corporation-Product Pipeline Review-2016

Interprotein Corporation-Product Pipeline Review-2016

  • Products Id :- GMDHC07984CDB
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Interprotein Corporation-Product Pipeline Review-2016', provides an overview of the Interprotein Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Interprotein Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of Interprotein Corporation

The report provides overview of Interprotein Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Interprotein Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Interprotein Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate Interprotein Corporation's strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Interprotein Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interprotein Corporation's pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Interprotein Corporation Snapshot 5

Interprotein Corporation Overview 5

Key Information 5

Key Facts 5

Interprotein Corporation-Research and Development Overview 6

Key Therapeutic Areas 6

Interprotein Corporation-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products-Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Interprotein Corporation-Pipeline Products Glance 14

Interprotein Corporation-Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Interprotein Corporation-Drug Profiles 16

IPC-003 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Small Molecules to Inhibit VEGF for Solid Tumors 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Small Molecule to Inhibit gp130 for Inflammation and Oncology 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Small Molecule to Inhibit IgE for Allergies 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Small Molecules to Inhibit RUNX1 for Acute Myeloid Leukemia 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Synthetic Peptide to Inhibit gp130 for Inflammation and Oncology 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Synthetic Peptides to Antagonize KIR for Oncology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Synthetic Peptides to Antagonize NKG2A for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Synthetic Peptides to Inhibit TIM-3 for Oncology 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Interprotein Corporation-Pipeline Analysis 25

Interprotein Corporation-Pipeline Products by Target 25

Interprotein Corporation-Pipeline Products by Route of Administration 26

Interprotein Corporation-Pipeline Products by Molecule Type 27

Interprotein Corporation-Pipeline Products by Mechanism of Action 28

Interprotein Corporation-Recent Pipeline Updates 29

Interprotein Corporation-Dormant Projects 30

Interprotein Corporation-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Figures

Interprotein Corporation-Pipeline by Indication, 2016 7

Interprotein Corporation-Pipeline by Stage of Development, 2016 8

Interprotein Corporation-Monotherapy Products in Pipeline, 2016 9

Interprotein Corporation-Pipeline by Target, 2016 25

Interprotein Corporation-Pipeline by Molecule Type, 2016 27

Interprotein Corporation-Pipeline Products by Mechanism of Action, 2016 28

List of Tables

Interprotein Corporation, Key Information 5

Interprotein Corporation, Key Facts 5

Interprotein Corporation-Pipeline by Indication, 2016 7

Interprotein Corporation-Pipeline by Stage of Development, 2016 8

Interprotein Corporation-Monotherapy Products in Pipeline, 2016 9

Interprotein Corporation-Partnered Products in Pipeline, 2016 10

Interprotein Corporation-Partnered Products/ Combination Treatment Modalities, 2016 11

Interprotein Corporation-Out-Licensed Products in Pipeline, 2016 12

Interprotein Corporation-Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Interprotein Corporation-Preclinical, 2016 14

Interprotein Corporation-Discovery, 2016 15

Interprotein Corporation-Pipeline by Target, 2016 25

Interprotein Corporation-Pipeline by Route of Administration, 2016 26

Interprotein Corporation-Pipeline by Molecule Type, 2016 27

Interprotein Corporation-Pipeline Products by Mechanism of Action, 2016 28

Interprotein Corporation-Recent Pipeline Updates, 2016 29

Interprotein Corporation-Dormant Developmental Projects,2016 30

Interprotein Corporation, Other Locations 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Interprotein Corporation; Interprotein Corporation - Key Therapeutics; Interprotein Corporation - Pipeline Overview and Promising Molecules; Interprotein Corporation - News; Interprotein Corporation - Latest Updates; Interprotein Corporation - Pipeline; Interprotein Corporation - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 108615
Site License
USD 3000 INR 217230
Corporate User License
USD 4500 INR 325845



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]